A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 427 participants.
Also called NCT02992288
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 427 participants
- Sponsor
- Registry
-
NCT02992288 -
2016-003839-38
-
- Other papers using this trial's data
- Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Bulgaria, Germany, Greece, Israel, Italy, Japan, Netherlands, Poland, Spain
- Registry status
- Completed
Technical summary
Registry record NCT02992288. Randomized; quadruple masking; primary purpose treatment. Start 2017-02-22 (actual); primary completion 2018-03-28 (actual). Results posted on 2019-04-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
- Acronym
- PANTHEON
- Condition
- Heart Failure
- Intervention (Drug)
- Neladenoson bialanate (BAY1067197)
- Intervention (Drug)
- Neladenoson bialanate (BAY1067197)
- Intervention (Drug)
- Neladenoson bialanate (BAY1067197)
- Intervention (Drug)
- Neladenoson bialanate (BAY1067197)
- Intervention (Drug)
- Neladenoson bialanate (BAY1067197)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct02992288- Content hash
1dda11d5a824d543bd197b21d3372f46950b81670db2c0a9c349905a17dda90c